SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Arrowhead Resarch
ARWR 42.39+0.2%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Paul Lee5/5/2015 5:30:27 PM
   of 172
 
Arrowhead Research announced that it completed dosing volunteers and will begin dosing patients in its on-going Phase 1 study of ARC-AAT (6.94 ) : Co will begin dosing patients in an on-going phase 1 study of ARC-AAT, the Company's clinical candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
  • The study was designed to begin dose escalation in healthy volunteers (Part A) and transition into patients (Part B) when a predefined knockdown target is achieved. That target is at least 30% reduction of serum AAT levels in 3 subjects or greater than 60% reduction in a single subject. This was met during the third cohort.
  • All three dose levels tested appear to be generally well tolerated and the data safety committee has cleared the study to move into patients with AATD. Dosing in patients may now begin at the highest dose level used in Part A and then continued dose escalation may proceed under the protocol.
  • The company expects to complete the Phase 1 study by the end of 2015.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News